Instil Bio, INC. 8-K Filing
Ticker: TIL · Form: 8-K · Filed: Apr 3, 2026 · CIK: 0001789769
| Field | Detail |
|---|---|
| Company | Instil Bio, INC. (TIL) |
| Form Type | 8-K |
| Filed Date | Apr 3, 2026 |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.000001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Instil Bio, INC. (ticker: TIL) to the SEC on Apr 3, 2026.
What are the key financial figures in this filing?
Key dollar amounts include: $0.000001 (nge on which registered Common Stock, $0.000001 par value TIL The Nasdaq Stock Market).
How long is this filing?
Instil Bio, INC.'s 8-K filing is 3 pages with approximately 768 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 768 words · 3 min read · ~3 pages · Grade level 12.4 · Accepted 2026-04-03 08:00:15
Key Financial Figures
- $0.000001 — nge on which registered Common Stock, $0.000001 par value TIL The Nasdaq Stock Market
Filing Documents
- til-20260401.htm (8-K) — 35KB
- seccessationofclient-audit.htm (EX-16.1) — 3KB
- 0001789769-26-000024.txt ( ) — 155KB
- til-20260401.xsd (EX-101.SCH) — 2KB
- til-20260401_lab.xml (EX-101.LAB) — 22KB
- til-20260401_pre.xml (EX-101.PRE) — 13KB
- til-20260401_htm.xml (XML) — 3KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant. On April 1, 2026, the Audit Committee of the Board of Directors of Instil Bio, Inc. (the "Company") approved the appointment of RSM US LLP ("RSM") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. This action resulted in the replacement of Deloitte & Touche LLP ("Deloitte") as the Company's independent registered public accounting firm, which the Audit Committee dismissed effective April 1, 2026. The reports of Deloitte on the Company's consolidated financial statements for the fiscal years ended December 31, 2025 and 2024 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. In connection with the audits of the Company's consolidated financial statements for the fiscal years ended December 31, 2025 and 2024, and in the subsequent period through April 1, 2026, there were no disagreements with Deloitte on any matters of accounting principles or practices, financial statement disclosure or auditing scope and procedures which, if not resolved to the satisfaction of Deloitte, would have caused Deloitte to make reference to the matter in their report. There were no reportable events (as that term is described in Item 304(a)(1)(v) of Regulation S-K) during the fiscal years ended December 31, 2025 and 2024, or in the subsequent period through April 1, 2026. The Company has provided a copy of the foregoing disclosures to Deloitte and requested that Deloitte furnish it with a letter addressed to the Securities and Exchange Commission stating whether Deloitte agrees with the above statements. A copy of Deloitte's letter, dated April 3, 2026, is filed as Exhibit 16.1 to this Form 8-K. During the two most recent fiscal years and in the subsequent interim period through April 1, 2026, neither the Company nor anyone on its behalf has consulted with RSM with resp
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 16.1 Letter from Deloitte & Touche LLP to the Securities and Exchange Commission dated April 3, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Instil Bio, Inc. Date: April 3, 2026 By: /s/ Sandeep Laumas, M.D. Sandeep Laumas, M.D. Chief Financial Officer and Chief Business Officer (Principal Financial Officer and Principal Accounting Officer)